Siga Technologies Inc. is a biotechnology company that focuses on the development and commercialization of novel therapeutics for health security threats. Its primary purpose is to address biological warfare and contagious disease outbreaks by providing pharmaceutical solutions. Siga Technologies is well-known for its product development in antiviral therapies, specifically targeting orthopoxvirus infections, which include smallpox and monkeypox. The company's flagship product is a smallpox antiviral known as TPOXX. Operating in a niche but critical sector, Siga plays a significant role in public health by enhancing global biodefense capabilities. Its contributions are crucial in supporting governmental and military contracts aimed at maintaining readiness against potential biological threats. Headquartered in the United States, Siga Technologies collaborates with various government agencies to ensure strategic stockpiling and availability of its medical countermeasures. The company's work is integral to enhancing national security and public safety, reinforcing the importance of emergency preparedness in the pharmaceutical and biotechnology industries.